Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M

Kiniksa Pharmaceuticals International, plc

ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.
2025 ARCALYST net product revenue guidance: $560M to $580M.
Approximately 13% of target 14,000 multiple-recurrence pericarditis patients actively on ARCALYST as of Q4 2024.
Cash, cash equivalents, and short-term investments of $243.6M as of Dec 31, 2024; expects to remain cash flow positive annually.
Over 2,850 prescribers have written ARCALYST prescriptions; average therapy duration ~27 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.